The production volume possible has doubled.
For an increasing range of large-molecule and biologics based therapeutic agents, manufacturing scale has an advantage, but only if process and capacity are well matched (and cost-effective) at commercial volumes. Offering scale, capacity and flexibility as leverage to meet those needs, integrated bioprocessing solutions manufacturer ABEC announced the release of a single-use bioreactor capable of 4,000-liter production volumes—doubling, claimed the company, the industry-standard 2,000-liter single use bioreactors in common application today.
ABEC commented on the increased capacity, noting. “The 4,000-liter capability is consistent with ABEC’s mission to provide the industry’s most productive and cost-effective solutions for biopharmaceutical manufacturing,” said Scott Pickering, ABEC’s President and CEO. “Rather than incur the costs needed to ‘scale-out’ capacity with multiple 2,000-liter systems, single use customers can now achieve true economies of scale.”
The 4,000-liter CSR bioreactor is used in cell culture, purification pooling, media prep and viral inactivation. The company has announced the performance in comparable to stainless steel systems.
